Rutgers Recruiting Participants For Pfizer COVID-19 Pediatric Bivalent Vaccine Clinical Trial
November 05, 2022
November 05, 2022
NEW BRUNSWICK, New Jersey, Nov. 5 (TNSres) -- Rutgers University issued the following news:
Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the safety and efficacy of the bivalent COVID-19 vaccines in children under age 5.
Although the U.S. Food and Drug Administration and Centers for Disease Control and Prevention have given early use authorization for the bivalent COVID-19 vaccine, children under 5 are still . . .
Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the safety and efficacy of the bivalent COVID-19 vaccines in children under age 5.
Although the U.S. Food and Drug Administration and Centers for Disease Control and Prevention have given early use authorization for the bivalent COVID-19 vaccine, children under 5 are still . . .